Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Severe alopecia areata involves higher levels of certain immune cells, which can be normalized with betamethasone.

PRP is effective for treating patchy alopecia areata.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

Adalimumab may cause severe hair loss in some patients.

New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.

Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.

Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.

Pediatric alopecia areata needs better treatments and psychological support.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

Early onset, severe types, nail changes, family history, and body hair loss worsen alopecia areata prognosis; sticking to treatment helps.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Certain gene variations might increase the risk of a hair loss condition in Koreans.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Alopecia areata often starts before age 20, is more common in women, and may have a genetic link with other autoimmune diseases.

A 300 mg monthly pulse of prednisolone effectively and safely treats widespread alopecia areata.

Alopecia areata treatment varies, with no optimal method established yet.

Diphenylcyclopropenone (DPCP) can help regrow hair in many alopecia areata patients but may cause side effects and relapses.

Certain HLA class II alleles increase or decrease the risk of alopecia areata.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.